Current Status and Growth of Nuclear Theranostics in Singapore

被引：1

作者：

Huang, Hian Liang ^{[1
,2
]}

Tong, Aaron Kian Ti ^{[1
,2
]}

Thang, Sue Ping ^{[1
,2
]}

Yan, Sean Xuexian ^{[1
,2
]}

Lam, Winnie Wing Chuen ^{[1
,2
]}

Loke, Kelvin Siu Hoong ^{[1
,2
]}

Tang, Charlene Yu Lin ^{[1
]}

Cheng, Lenith Tai Jit ^{[1
]}

Ooi, Gideon Su Kai ^{[1
]}

Low, Han Chung ^{[1
]}

Magsombol, Butch Maulion ^{[1
]}

Tham, Wei Ying ^{[1
,2
]}

Goh, Charles Xian Yang ^{[1
,2
]}

Tan, Colin Jingxian ^{[1
]}

Khor, Yiu Ming ^{[1
,2
]}

Zaheer, Sumbul ^{[1
,2
]}

Bharadwaj, Pushan ^{[1
,2
]}

Xie, Wanying ^{[1
,2
]}

Ng, David Chee Eng ^{[1
,2
]}

机构：

[1] Singapore Gen Hosp, Dept Nucl Med & Mol Imaging, 1 Outram Rd, Singapore 169608, Singapore

[2] Duke NUS Grad Med Sch, 8 Coll Rd, Singapore 169857, Singapore

来源：

NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 53卷 / 02期

关键词：

Theranostic; Singapore; Radioiodine; Lutetium; Yttrium; Radium; RESISTANT PROSTATE-CANCER; RECEPTOR RADIONUCLIDE THERAPY; RADIOEMBOLIZATION Y-90 PET/CT; RADIOLIGAND THERAPY; NEUROENDOCRINE TUMORS; PREDICTIVE DOSIMETRY; SURVIVAL; PSMA; ENZALUTAMIDE; PREDNISONE;

D O I：

10.1007/s13139-019-00580-3

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of 'personalised' medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.

引用

页码：96 / 101

页数：6

共 32 条

[1] Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].

Ahmadzadehfar, Hojjat ;

Rahbar, Kambiz ;

Kuerpig, Stefan ;

Boegemann, Martin ;

Claesener, Michael ;

Eppard, Elisabeth ;

Gaertner, Florian ;

Rogenhofer, Sebastian ;

Schaefers, Michael ;

Essler, Markus .

EJNMMI RESEARCH, 2015, 5 :1-8

[2] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

[3] Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study [J].

Beer, Tomasz M. ;

Armstrong, Andrew J. ;

Rathkopf, Dana ;

Loriot, Yohann ;

Sternberg, Cora N. ;

Higano, Celestia S. ;

Iversen, Peter ;

Evans, Christopher P. ;

Kim, Choung-Soo ;

Kimura, Go ;

Miller, Kurt ;

Saad, Fred ;

Bjartell, Anders S. ;

Borre, Michael ;

Mulders, Peter ;

Tammela, Teuvo L. ;

Parli, Teresa ;

Sari, Suha ;

van Os, Steve ;

Theeuwes, Ad ;

Tombal, Bertrand .

EUROPEAN UROLOGY, 2017, 71 (02) :151-154

[4] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[5] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer [J].

Fendler, Wolfgang P. ;

Reinhardt, Svenja ;

Ilhan, Harun ;

Delker, Andreas ;

Boening, Guido ;

Gildehaus, Franz J. ;

Stief, Christian ;

Bartenstein, Peter ;

Gratzke, Christian ;

Lehner, Sebastian ;

Rominger, Axel .

ONCOTARGET, 2017, 8 (02) :3581-3590

[6] Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer [J].

Heck, Matthias M. ;

Tauber, Robert ;

Schwaiger, Sebastian ;

Retz, Margitta ;

D'Alessandria, Calogero ;

Maurer, Tobias ;

Gafita, Andrei ;

Wester, Hans-Juergen ;

Gschwend, Juergen E. ;

Weber, Wolfgang A. ;

Schwaiger, Markus ;

Knorr, Karina ;

Eiber, Matthias .

EUROPEAN UROLOGY, 2019, 75 (06) :920-926

[7] Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer [J].

Heck, Matthias M. ;

Retz, Margitta ;

D'Alessandria, Calogero ;

Rauscher, Isabel ;

Scheidhauer, Klemens ;

Maurer, Tobias ;

Storz, Enno ;

Janssen, Friederike ;

Schottelius, Margret ;

Wester, Hans-Juergen ;

Gschwend, Juergen E. ;

Schwaiger, Markus ;

Tauber, Robert ;

Eiber, Matthias .

JOURNAL OF UROLOGY, 2016, 196 (02) :382-390

[8] [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study [J].

Hofman, Michael S. ;

Violet, John ;

Hicks, Rodney J. ;

Ferdinandus, Justin ;

Thang, Sue Ping ;

Akhurst, Tim ;

Iravani, Amir ;

Kong, Grace ;

Kumar, Aravind Ravi ;

Murphy, Declan G. ;

Eu, Peter ;

Jackson, Price ;

Scalzo, Mark ;

Williams, Scott G. ;

Sandhu, Shahneen .

LANCET ONCOLOGY, 2018, 19 (06) :825-833

[9] Image-Guided Personalized Predictive Dosimetry by Artery-Specific SPECT/CT Partition Modeling for Safe and Effective 90Y Radioembolization [J].

Kao, Yung Hsiang ;

Tan, Andrew Eik Hock ;

Burgmans, Mark Christiaan ;

Irani, Farah Gillian ;

Khoo, Li Ser ;

Lo, Richard Hoau Gong ;

Tay, Kiang Hiong ;

Tan, Bien Soo ;

Chow, Pierce Kah Hoe ;

Ng, David Chee Eng ;

Goh, Anthony Soon Whatt .

JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (04) :559-566

[10] Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres [J].

Kao, Yung-Hsiang ;

Steinberg, Jeffrey D. ;

Tay, Young-Soon ;

Lim, Gabriel K. Y. ;

Yan, Jianhua ;

Townsend, David W. ;

Budgeon, Charley A. ;

Boucek, Jan A. ;

Francis, Roslyn J. ;

Cheo, Timothy S. T. ;

Burgmans, Mark C. ;

Irani, Farah G. ;

Lo, Richard H. G. ;

Tay, Kiang-Hiong ;

Tan, Bien-Soo ;

Chow, Pierce K. H. ;

Satchithanantham, Somanesan ;

Tan, Andrew E. H. ;

Ng, David C. E. ;

Goh, Anthony S. W. .

EJNMMI RESEARCH, 2013, 3 :1-27

← 1 2 3 4 →